Schizophrenia
... have the disorder Risk increased if person is single, industrialised nation, in lower SE class, urban, problems in utero, perinatal problems, born in winter, recent stressful life event ...
... have the disorder Risk increased if person is single, industrialised nation, in lower SE class, urban, problems in utero, perinatal problems, born in winter, recent stressful life event ...
Alcohol Abuse: New Approaches to Treatment
... Preliminary studies suggest that olanzapine decreases craving for alcohol Anecdotal evidence in the literature suggests that olanzapine (and its cousin clozapine) decrease substance use Olanzapine is also a 5-HT3 antagonist very much like ondansetron Ability to sleep at night and appetite stimulatio ...
... Preliminary studies suggest that olanzapine decreases craving for alcohol Anecdotal evidence in the literature suggests that olanzapine (and its cousin clozapine) decrease substance use Olanzapine is also a 5-HT3 antagonist very much like ondansetron Ability to sleep at night and appetite stimulatio ...
INVESTIGATION OF WEIGHT GAIN AMONG PSYCHOTIC
... via diminished physical activity, due to their sedative effects (19). Drugs with high H1 receptor affinity have sedative effects, leading some investigators to speculate that sedation may induce weight gain because of reduced mobility(20) .Sedation can impair a person's ability to function normally ...
... via diminished physical activity, due to their sedative effects (19). Drugs with high H1 receptor affinity have sedative effects, leading some investigators to speculate that sedation may induce weight gain because of reduced mobility(20) .Sedation can impair a person's ability to function normally ...
Numbers-needed-to-treat analysis: an explanation using
... CATIE, it should be noted that participants were not randomised to perphenazine if they had extrapyramidal side-effect markers such as tardive dyskinesia. In phase 1 of CATIE the most ‘effective’ anti psychotic (and the only one significantly different from perphenazine) was olanzapine. However, ol ...
... CATIE, it should be noted that participants were not randomised to perphenazine if they had extrapyramidal side-effect markers such as tardive dyskinesia. In phase 1 of CATIE the most ‘effective’ anti psychotic (and the only one significantly different from perphenazine) was olanzapine. However, ol ...
What CATIE Found: Results From the Schizophrenia Trial
... The authors provide an overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health. CATIE was designed to compare a proxy first-generation antipsychotic, perphenazine, to several newer drugs. In phase 1 of the trial, consen ...
... The authors provide an overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sponsored by the National Institute of Mental Health. CATIE was designed to compare a proxy first-generation antipsychotic, perphenazine, to several newer drugs. In phase 1 of the trial, consen ...
Psychiatric Illness
... a group of serious illnesses that affect the mind – they can alter a person's ability to think clearly, make good judgments, respond emotionally, communicate effectively, understand reality, and behave appropriately. When symptoms are severe, people with psychotic disorders have difficulty staying i ...
... a group of serious illnesses that affect the mind – they can alter a person's ability to think clearly, make good judgments, respond emotionally, communicate effectively, understand reality, and behave appropriately. When symptoms are severe, people with psychotic disorders have difficulty staying i ...
presentation ( format)
... • 1460 “real-world” schizophrenics (no first-break schizophrenics) • NIMH funded • Comparison of second generation antipsychotics to a representative first generation antipsychotic (perphenazine). Agent ...
... • 1460 “real-world” schizophrenics (no first-break schizophrenics) • NIMH funded • Comparison of second generation antipsychotics to a representative first generation antipsychotic (perphenazine). Agent ...
Steinberg – Medication Management of Behaviors in RCFEs
... Animal-assisted therapy: Potential for benefit but no rigorous evidence Exercise: Improvement in sleep and other parameters but no consistent effect on behavior ____________________________________________ Wandering: Exercise, Walking not helpful. Tracking devices, alarms, motion detectors eff ...
... Animal-assisted therapy: Potential for benefit but no rigorous evidence Exercise: Improvement in sleep and other parameters but no consistent effect on behavior ____________________________________________ Wandering: Exercise, Walking not helpful. Tracking devices, alarms, motion detectors eff ...
see p. Psy9 - Viktor`s Notes for the Neurosurgery Resident
... LOXAPINE inhalation powder 10 mg is FDA approved for acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. N.B. atypical neuroleptics increase mortality* of elderly patients with dementia-related psychosis *most deaths are cardiovascular (e.g. heart failure, s ...
... LOXAPINE inhalation powder 10 mg is FDA approved for acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. N.B. atypical neuroleptics increase mortality* of elderly patients with dementia-related psychosis *most deaths are cardiovascular (e.g. heart failure, s ...
![Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)](http://s1.studyres.com/store/data/008004324_1-4687ab11684bc08b6291bceb18fec16a-300x300.png)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
... medical intervention is not immediately provided. There are no tests to predict whether an individual is susceptible to developing NMS when exposed to an antipsychotic. Thus NMS must be recognized early because it is a medical emergency that requires immediate discontinuation of the antipsychotic, h ...
... medical intervention is not immediately provided. There are no tests to predict whether an individual is susceptible to developing NMS when exposed to an antipsychotic. Thus NMS must be recognized early because it is a medical emergency that requires immediate discontinuation of the antipsychotic, h ...
National Initiative Examines Antipsychotic Drug Use
... mortality in elderly patients treated for dementia-related psychosis. The FDA warning is based on a review of 17 placebo-controlled trials studying 5,377 elderly patients with dementia-related behavioral disorders. The studies reported a 1.6 to 1.7 times greater increase in death with the use of aty ...
... mortality in elderly patients treated for dementia-related psychosis. The FDA warning is based on a review of 17 placebo-controlled trials studying 5,377 elderly patients with dementia-related behavioral disorders. The studies reported a 1.6 to 1.7 times greater increase in death with the use of aty ...
Use of Atypical Antipsychotics in Pediatric Patients PDF, 70.82 KB
... use of asenapine and iloperidone in pediatric patients and these agents are not further discussed. Clinical Efficacy and Safety Atypical agents are similar to conventional drugs in reducing psychotic symptoms (and may be more effective in reducing so-called negative symptoms). Although they produce ...
... use of asenapine and iloperidone in pediatric patients and these agents are not further discussed. Clinical Efficacy and Safety Atypical agents are similar to conventional drugs in reducing psychotic symptoms (and may be more effective in reducing so-called negative symptoms). Although they produce ...
BIPOLAR DISORDER - New York State Academy of Family
... Overall First line drugs have better response than placebo Efficacy similar across first line medications Lithium associated with reduced risk of suicide attempts Monotherapy maybe sufficient for less severely ill patients Combination therapy frequently for pts with manic or mixed episodes Combinati ...
... Overall First line drugs have better response than placebo Efficacy similar across first line medications Lithium associated with reduced risk of suicide attempts Monotherapy maybe sufficient for less severely ill patients Combination therapy frequently for pts with manic or mixed episodes Combinati ...
Overview of the Brain and Psychiatric Illnesses by Dr. Daniel Healy
... olanzapine (Zyprexa) (mania) olanzapine + fluoxetine (depression) ...
... olanzapine (Zyprexa) (mania) olanzapine + fluoxetine (depression) ...
Atypical Antipsychotic Drug Use in Children and Adolescents
... Sikich, L., Hamer, R. et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a doubleblind, randomized, 8-week trial. 2004; Neuropsychopharmacology 29: 133-145. Sivaprasad, L., Hassan, T., Handy, S. Survey of atypical antipsychotic medication use by child and adolescent ...
... Sikich, L., Hamer, R. et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a doubleblind, randomized, 8-week trial. 2004; Neuropsychopharmacology 29: 133-145. Sivaprasad, L., Hassan, T., Handy, S. Survey of atypical antipsychotic medication use by child and adolescent ...
ANTIPSYCHOYIC ( Neuroleptic ) DRUGS
... Sedation due to H1 receptor blockade 4- Quinidine –like actions ...
... Sedation due to H1 receptor blockade 4- Quinidine –like actions ...
Anti-Psychotic Use in AD: Implications from CATIE
... A more recent Cochrane review of haloperidol for the treatment of agitation in patients with dementia found that aggression was reduced, but there were no improvements in agitation, behavioral symptoms as a whole, or in clinical global impression. Because tolerability is frequently reduced in the el ...
... A more recent Cochrane review of haloperidol for the treatment of agitation in patients with dementia found that aggression was reduced, but there were no improvements in agitation, behavioral symptoms as a whole, or in clinical global impression. Because tolerability is frequently reduced in the el ...
Antipsychotic Use in the Elderly - Blue Cross and Blue Shield of
... increased risk of mortality in elderly patients treated for dementia-related psychosis. The FDA warning is based on a review of 17 placebo-controlled trials studying 5,377 elderly patients with dementia-related behavioral disorders. The studies reported a 1.6 to 1.7 times greater increase in death w ...
... increased risk of mortality in elderly patients treated for dementia-related psychosis. The FDA warning is based on a review of 17 placebo-controlled trials studying 5,377 elderly patients with dementia-related behavioral disorders. The studies reported a 1.6 to 1.7 times greater increase in death w ...
Antipsychotics
... NMS is an uncommon but serious and potentially fatal complication of therapy It is a syndrome of EPS, hyperthermia, altered consciousness, and autonomic changes (tachycardia, ...
... NMS is an uncommon but serious and potentially fatal complication of therapy It is a syndrome of EPS, hyperthermia, altered consciousness, and autonomic changes (tachycardia, ...
Schizophrenia and Psychotic Disorders ppt chap 21
... overwhelmed and overloaded. • Stage 2: restricted consciousness:depression is coupled with anxiety and withdrawal. Crucial to intervene during stage 1 or 2 • Stage 3: disinhibition: emergence of hallucinations and delusions that patient can no longer control. (first appearance of psychotic features) ...
... overwhelmed and overloaded. • Stage 2: restricted consciousness:depression is coupled with anxiety and withdrawal. Crucial to intervene during stage 1 or 2 • Stage 3: disinhibition: emergence of hallucinations and delusions that patient can no longer control. (first appearance of psychotic features) ...
Document
... those with mood-stabilizing properties, in combination with new antipsychotics, the possibility of a pharmacokinetic interaction between these compounds should be investigated. The results of the present study indicate that OXC does not affect the elimination of the newer atypical antipsychotic risp ...
... those with mood-stabilizing properties, in combination with new antipsychotics, the possibility of a pharmacokinetic interaction between these compounds should be investigated. The results of the present study indicate that OXC does not affect the elimination of the newer atypical antipsychotic risp ...
Dr Darton Presentation
... tardive dyskinesia, loss of fine control • Akathisia • Prolactin – breast development; lactation sexual side effects • Heart effects – disturbances of heart rhythm ...
... tardive dyskinesia, loss of fine control • Akathisia • Prolactin – breast development; lactation sexual side effects • Heart effects – disturbances of heart rhythm ...
Off-Label Use of Atypical Antipsychotics: An Update
... treatment of Tourette’s syndrome in adults. Evidence is stronger that atypical antipsychotics do not increase body weight in anorexia nervosa (although weight gain is a common adverse effect in other patients) or reduce substance abuse. There is little evidence about optimal dosages and durations of ...
... treatment of Tourette’s syndrome in adults. Evidence is stronger that atypical antipsychotics do not increase body weight in anorexia nervosa (although weight gain is a common adverse effect in other patients) or reduce substance abuse. There is little evidence about optimal dosages and durations of ...
Olanzapine
Olanzapine (originally branded Zyprexa) is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.Olanzapine is structurally similar to clozapine and quetiapine, but is classified as a thienobenzodiazepine. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company; the drug went generic in 2011. Sales of Zyprexa in 2008 were $2.2B in the US, and $4.7B worldwide.